王君,李毅刚

• 1:上海交通大学医学院附属新华医院心内科
• 2:上海交通大学心律失常诊治中心

摘要(Abstract)：

<正>植入式心律转复除颤器(ICD)于1980年由Mirowski等[1]首次植入人体并应用于临床,30多年来,ICD技术不断进步,功能日臻完善。同时大规模随机对照临床试验证实ICD可以有效终止恶性心律失常的发作、显著降低心脏性猝死(SCD)的发生,如今ICD已经广泛应用于SCD的一级和二级预防。目前,绝大多数的ICD植入都采用经静脉电极导线系统,通过外周静脉将电极导线置入右心室。

关键词(KeyWords)： 全皮下植入式心律转复除颤器;房性心动过速;室性心动过速

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王君,李毅刚

参考文献(References)：

• [1]Mirowski M,Reid PR,Mower MM,et al.Termination of Malignant Ventricular Arrhythmias with an Implanted Automatic Defi brillator in Human Beings.N Engl J Med,1980,303:322-324.
• [2]Curtis JP,Luebbert JJ,Wang Y,et al.Association of physician certifi cation and outcomes among patients receiving an implantable cardioverter-defi brillator.JAMA,2009,301:1661-1670.
• [3]Kleemann T,Becker T,Doenges K,et al.Annual rate of transvenous defi brillation lead defects in implantable cardioverter-defi brillators over a period of>10 years.Circulation,2007,115:2474-2480.
• [4]程姝娟,柳景华.心脏植入式电子装置的远程随访与检测.中国介入心脏病学杂志,2012,20:291-293.
• [5]Bardy GH,Smith WM,Hood MA,et al.An Entirely Subcutaneous Implantable Cardioverter–Defi brillator.N Engl J Med,2010,363:36-44.
• [6]Dabiri AL,Theuns DA,Valk SD,et al.Clinical experience with a novel subcutaneous implantable defibrillator system in a single center.Clin Res Cardiol,2011,100:737-744.
• [7]Aydin A,Hartel F,Schluter M,et al.Shock effi cacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death:initial multicenter experience.Circ Arrhythm Electrophysiol,2012,5:913-919.
• [8]Olde Nordkamp LR,Dabiri Abkenari L,Boersma LV,et al.The entirely subcutaneous implantable cardioverter-defi brillator:initial clinical experience in a large Dutch cohort.J Am Coll Cardiol,2012,60:1933-1939.
• [9]K?be J,Reinke F,Meyer C,et al.Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverterdefi brillators:a multicenter case-control study.Heart Rhythm,2013,10:29-36.
• [10]Jarman JW,Todd DM.United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology:important lessons to learn.Europace,2013,15:1158-1165.
• [11]Weiss R,Knight BP,Gold MR,et al.Safety and effi cacy of a totally subcutaneous implantable-cardioverter defibrillator.Circulation,2013,128:944-953.
• [12]Jarman JW,Lascelles K,Wong T,et al.Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults:cause for caution.Eur Heart J,2012,33:1351-1359.
• [13]Pedersen SS,Lambiase P,Boersma LV,et al.Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD:design and rationale of the EFFORTLESS S-ICD Registry.Pacing Clin Electrophysiol,2012,35:574-579.
• [14]Lambiase PD,Barr C,Theuns DA,et al.Worldwide experience with a totally subcutaneous implantable defi brillator:early results from the EFFORTLESS S-ICD Registry.Eur Heart J,2014,35:1657-1665.
• [15]Olde Nordkamp LR,Knops RE,Bardy GH,et al.Rationale and design of the PRAETORIAN trial:A Prospective,RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defi brillator therapy.Am Heart J,2012,163:753-760.
• [16]Gold MR,Theuns DA,Knight BP,et al.Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms:the START study.J Cardiovasc Electrophysiol,2012,23:359-366.